Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com -- SciSparc Ltd. (NASDAQ:SPRC) stock surged 34.5% on Wednesday after the clinical-stage pharmaceutical company announced a definitive agreement to acquire a controlling interest in Canadian-listed Miza III Ventures Inc. (TSXV:MIZA.P).
Under the terms of the agreement dated October 9, 2025, SciSparc will transfer its advanced clinical-stage pharmaceutical portfolio and its approximately 51% equity stake in SciSparc Nutraceuticals to Miza. In exchange, SciSparc will receive 63,300,000 common shares of Miza and up to 48,000,000 contingent rights based on pre-determined milestones.
The deal values Miza’s enterprise at approximately $3.3 million, while SciSparc’s transferred assets are valued at approximately $11.6 million. Following the transaction’s completion, SciSparc is expected to hold between 75% and 84% of Miza, which plans to rename itself "NeuroThera Labs Inc."
The TSX Venture Exchange has conditionally approved the transaction, which is anticipated to close around October 22, 2025. Upon closing, SciSparc or a third party intends to commit up to CAD1,000,000 (approximately $716,000) to Miza through an unsecured convertible note bearing 7% annual interest.
Additionally, Miza will issue 4,000,000 common share purchase warrants to SciSparc at closing, exercisable at CAD0.25 per share over a five-year period.
SciSparc’s transferred pharmaceutical portfolio includes treatments for Tourette syndrome, Alzheimer’s disease, and autism, with various clinical trials either underway or completed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.